Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
3.429
+0.059 (1.74%)
Aug 30, 2024, 4:00 PM EDT - Market closed
Aprea Therapeutics Revenue
Aprea Therapeutics had revenue of $561.57K in the quarter ending June 30, 2024, with 124.91% growth. This brings the company's revenue in the last twelve months to $1.28M, up 410.91% year-over-year. In the year 2023, Aprea Therapeutics had annual revenue of $583.23K.
Revenue (ttm)
$1.28M
Revenue Growth
+410.91%
P/S Ratio
11.83
Revenue / Employee
$182,241
Employees
7
Market Cap
18.62M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 583.23K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAPRE News
- 3 days ago - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference - GlobeNewsWire
- 19 days ago - Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 - GlobeNewsWire
- 2 months ago - Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 - GlobeNewsWire
- 3 months ago - Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial - GlobeNewsWire
- 3 months ago - Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 3 months ago - Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 4 months ago - Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D. - GlobeNewsWire